Aprea Therapeutics Stock (NASDAQ:APRE)

Forecast Revenue Ownership Financials Chart

Previous Close

$0.75

52W Range

$0.55 - $2.22

50D Avg

$0.85

200D Avg

$1.03

Market Cap

$4.97M

Avg Vol (3M)

$368.79K

Beta

1.56

Div Yield

APRE Company Profile

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 03, 2019

Website

APRE Performance

APRE Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$1.50M	$583.23K
Operating Income	$-13.23M	$-14.32M	$-15.47M
Net Income	$-12.60M	$-12.96M	$-14.29M
EBITDA	$-13.23M	$-14.30M	$-14.28M
Basic EPS	$-1.93	$-2.35	$-3.95
Diluted EPS	$-1.93	$-2.35	$-3.95

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
CELZ	Creative Medical Technology Holdings, Inc.
HCWB	HCW Biologics Inc.
RNAZ	TransCode Therapeutics, Inc.
APVO	Aptevo Therapeutics Inc.
ACXP	Acurx Pharmaceuticals, Inc.
INAB	IN8bio, Inc.
KPRX	Kiora Pharmaceuticals, Inc.
ADIL	Adial Pharmaceuticals, Inc.
BCDA	BioCardia, Inc.
GLTO	Galecto, Inc.